All results
1 results for randomized multicenter open label phase iii study evaluate efficacy and safety
-
ALXN2050-NEPH-201
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy…
- Ages
- 18 Years - 75 Years
- Sexes
- All